An update on oral drug delivery via intestinal lymphatic transport
| Autor: | Wei Wu, Yi Lu, Zichen Zhang, Jianping Qi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oral
Drug Microfold cell media_common.quotation_subject RM1-950 Bioinformatics Systemic circulation Chylomicron 03 medical and health sciences Lymphatic transport 0302 clinical medicine Medicine General Pharmacology Toxicology and Pharmaceutics Drug absorption 030304 developmental biology media_common Drug transport 0303 health sciences business.industry Lymphatic system 030220 oncology & carcinogenesis Drug delivery Therapeutics. Pharmacology business Oral retinoid Drug metabolism |
| Zdroj: | Acta Pharmaceutica Sinica B, Vol 11, Iss 8, Pp 2449-2468 (2021) |
| ISSN: | 2211-3835 |
| DOI: | 10.1016/j.apsb.2020.12.022 |
| Popis: | Orally administered drug entities have to survive the harsh gastrointestinal environment, penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism. The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway. Intestinal lymphatic transport is emerging as a promising pathway to this end. In this review, we intend to provide an updated overview on the rationale, strategies, factors and applications involved in intestinal lymphatic transport. There are mainly two pathways for peroral lymphatic transport—the chylomicron and the microfold cell pathways. The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|